Librela (bedinvetmab) is a monoclonal antibody injection that represents a fundamentally different approach to managing osteoarthritis (OA) pain in dogs. Rather than using traditional anti-inflammatory drugs like NSAIDs, Librela works by targeting a specific pain-signalling protein called nerve growth factor (NGF). Since its FDA approval in May 2023, over one million dogs in the United States have been treated with Librela, and over 18 million doses have been distributed globally.
This guide covers how Librela works, what the clinical evidence shows, what it costs, and --- critically --- what every owner needs to know about the February 2025 label update that added neurologic adverse events and reports of death to the product information.
What Is Librela?
| Parameter | Detail |
|---|---|
| Generic name | Bedinvetmab |
| Drug class | Monoclonal antibody (anti-NGF) |
| Manufacturer | Zoetis |
| FDA approved | May 2023 |
| Species | Dogs only |
| Indication | Control of pain associated with osteoarthritis in dogs |
| Administration | Subcutaneous injection given at the veterinary clinic |
| Dosing | Once monthly, dosed by body weight |
| Onset | Many dogs show improvement within the first week; peak effect by 2—4 weeks |
Librela is the first monoclonal antibody approved by the FDA for use in dogs. It is a “caninised” antibody, meaning it is designed to closely match the structure of natural dog antibodies, which should minimise immune reactions.
How It Works
Nerve growth factor (NGF) is a protein that plays a central role in OA pain signalling. In arthritic joints, NGF levels are elevated, and NGF sensitises pain receptors, making them fire more easily and intensely. This contributes to the chronic pain, stiffness, and reduced mobility that characterise osteoarthritis.
Librela binds to NGF and neutralises it before it can activate pain receptors. This interrupts the pain signal at its source, providing relief without the anti-inflammatory mechanism of NSAIDs.
Key distinction from NSAIDs: Because Librela does not inhibit prostaglandins or cyclooxygenase enzymes, it does not carry the same risk of gastrointestinal ulceration, kidney damage, or liver toxicity that is associated with NSAID use. This makes it an important option for dogs that cannot tolerate NSAIDs.
Clinical Efficacy: What the Evidence Shows
Pivotal Study Results
In Zoetis’s pivotal clinical trial, dogs receiving Librela showed statistically significant improvement in pain scores compared to placebo. Owners reported increased mobility, willingness to play, improved comfort, and better quality of life.
Real-World Experience
Since its launch, Librela has become one of the fastest-growing veterinary products globally. Many veterinarians report seeing meaningful improvements in dogs that had limited response to NSAIDs alone. However, as with all medications, response varies:
- Some dogs show dramatic improvement --- owners describe dogs acting “years younger,” returning to activities they had stopped, and showing visible comfort within days.
- Some dogs show moderate improvement --- noticeable but not transformative.
- Some dogs do not respond --- a subset of dogs do not show meaningful improvement after one or more monthly injections.
Most veterinarians recommend trying at least two to three monthly injections before concluding that a dog is a non-responder, as the cumulative effect of consecutive doses may be needed.
February 2025 Label Update: What Owners Need to Know
On February 18, 2025, the FDA published safety-related labelling changes for Librela. This update is significant and every owner considering or currently using Librela should be informed about it.
What Was Added to the Label
The updated label now includes the following adverse events that have been reported in dogs receiving Librela:
- Neurological adverse events: ataxia (loss of coordination), seizures, paresis (partial paralysis), proprioception deficits (difficulty sensing body position), and paralysis
- Death: In some cases, death (including euthanasia) has been reported as an outcome of the listed adverse events
Context and Perspective
This label update requires balanced interpretation:
These are reported events, not necessarily proven to be caused by Librela. Adverse event reports collected through pharmacovigilance systems document temporal associations --- a dog received Librela and subsequently developed a neurological problem. This does not always mean the drug caused the problem. OA is most common in older dogs, who are also at higher risk for neurological conditions (such as degenerative myelopathy, spinal disease, and seizure disorders) regardless of medication.
However, the reports warranted a label change. The FDA determined that the pattern and nature of reported adverse events were sufficient to update the product label. This is a meaningful regulatory action that signals the reports should be taken seriously.
The overall incidence appears to be low relative to the number of dogs treated. Over 18 million doses have been distributed globally and over one million dogs have been treated in the US. The absolute number of neurologic adverse event reports, while concerning, represents a small fraction of total doses administered. However, exact incidence rates from spontaneous reporting systems are difficult to calculate because underreporting is common.
What This Means for Your Decision
The label update does not mean Librela is unsafe for all dogs. It means that:
- Informed consent is now more important than ever. Your veterinarian should discuss the potential for neurologic adverse events before starting Librela.
- Monitoring is essential. Watch for changes in coordination, gait, strength, or any new neurological signs after each injection.
- Report any concerns. If your dog develops new neurological symptoms after a Librela injection, contact your veterinarian immediately and request that the event be reported to Zoetis and the FDA.
- Risk-benefit analysis is individual. For a dog with debilitating OA pain that cannot tolerate NSAIDs, the benefit of effective pain control may outweigh the small risk of adverse events. For a dog with mild OA and multiple effective treatment options, the calculus may be different.
Dogs That May Warrant Extra Caution
While the label does not list specific contraindications for neurological conditions, extra consideration should be given to:
- Dogs with pre-existing seizure disorders
- Dogs with known spinal cord disease or degenerative myelopathy
- Dogs with a history of neurological events
- Dogs on other medications that affect the nervous system
Discuss your dog’s individual risk factors with your veterinarian.
Cost
| Dog Size | Approximate Cost Per Injection | Monthly Cost |
|---|---|---|
| Small dogs (<20 lbs) | $90—130 | $90—130 |
| Medium dogs (20—60 lbs) | $110—170 | $110—170 |
| Large dogs (60—100 lbs) | $150—220 | $150—220 |
| Giant breeds (100+ lbs) | $180—250+ | $180—250+ |
Costs vary by veterinary practice and geographic region. Some practices include the injection administration fee in the product price; others charge a separate injection or office visit fee. Librela is administered at the vet clinic and is not available for home use.
Cost Comparison with Other OA Treatments
| Treatment | Approximate Monthly Cost | Administration |
|---|---|---|
| Librela | $90—250 | Monthly vet injection |
| Carprofen (generic Rimadyl) | $10—25 | Daily oral tablet at home |
| Meloxicam (generic) | $15—40 | Daily oral liquid or tablet at home |
| Galliprant | $60—100 | Daily oral tablet at home |
| Adequan (injectable) | $50—80 per injection (loading series, then as-needed) | Intramuscular injection at vet |
| Dasuquin (supplement) | $30—60 | Daily oral supplement at home |
Librela is significantly more expensive than generic NSAIDs. The value proposition is strongest for dogs that cannot tolerate NSAIDs, dogs whose owners prefer the convenience of a monthly injection over daily pills, or dogs that have not responded adequately to other treatments.
Librela vs Other OA Pain Treatments
Librela vs NSAIDs (Carprofen, Meloxicam, Galliprant)
| Factor | Librela | NSAIDs |
|---|---|---|
| Mechanism | Anti-NGF monoclonal antibody | COX/prostaglandin inhibition |
| GI risk | Low | Moderate to high (ulceration, diarrhoea) |
| Kidney/liver risk | Low | Requires monitoring |
| Administration | Monthly injection at vet | Daily oral at home |
| Cost | Higher | Lower (especially generics) |
| Neurologic AE risk | Reported (see label update) | Generally low |
| Blood monitoring needed | No | Yes (kidney/liver values) |
Librela vs Adequan
Adequan (polysulfated glycosaminoglycan) is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) for dogs. It works within the joint to inhibit cartilage-degrading enzymes and stimulate repair. Librela provides pain relief but is not classified as a DMOAD. Some veterinarians use both together --- Adequan to address joint disease progression and Librela for pain control.
Can Librela Be Combined with Other Treatments?
Yes. Librela can be used alongside:
- NSAIDs (many vets use both for multimodal pain management)
- Gabapentin (for neuropathic pain)
- Joint supplements (glucosamine, chondroitin, fish oil)
- Adequan
- Physical rehabilitation, weight management, and laser therapy
Multimodal pain management --- using multiple treatments that target different aspects of pain --- is the gold standard for canine OA management.
What About Cats? Solensia
Cats with osteoarthritis have a separate product: Solensia (frunevetmab), also made by Zoetis. Solensia is the first FDA-approved treatment for OA pain in cats and works through the same anti-NGF mechanism. In clinical trials, 77% of cat owners reported visible improvement within three monthly injections.
Librela is for dogs only. Solensia is for cats only. The antibodies are species-specific and cannot be used interchangeably.
What Is Coming Next: Lenivia
Zoetis is developing Lenivia (izenivetmab), a next-generation anti-NGF monoclonal antibody for dogs that lasts three months per injection instead of Librela’s one month. Lenivia received EU marketing authorisation in December 2025 and Canadian approval in 2025. US FDA approval is still pending. If approved, Lenivia could reduce vet visits from monthly to quarterly for OA pain management.
Frequently Asked Questions
How quickly does Librela work?
Many owners notice improvement within the first week. Peak effect typically occurs by 2—4 weeks after injection. Some dogs require two or three consecutive monthly injections before the full benefit is apparent.
What if Librela stops working?
Some owners report that efficacy seems to diminish over time. If you notice decreased effectiveness, discuss with your vet. Options may include adding complementary treatments (NSAIDs, gabapentin, physical therapy) or adjusting the overall pain management plan.
Can Librela cure arthritis?
No. Librela controls pain but does not reverse joint damage or cure the underlying disease. OA is progressive, and ongoing management --- including weight control, appropriate exercise, and possibly multiple therapies --- is typically needed long-term.
Is Librela safe for puppies or young dogs?
Librela is approved for dogs with OA, which is predominantly a condition of middle-aged to older dogs. Safety and efficacy have not been established in very young dogs, pregnant dogs, or lactating dogs. Discuss with your veterinarian.
My dog had a seizure after a Librela injection. What should I do?
Seek immediate veterinary care. A seizure is a serious event regardless of cause. Your veterinarian should evaluate your dog, provide appropriate treatment, and report the adverse event to Zoetis and the FDA. Further Librela injections should be carefully reconsidered in discussion with your vet.
Do I need to keep giving Librela every month?
Librela’s effect wears off over approximately 4—6 weeks. If you stop injections, your dog’s pain will likely return as NGF activity resumes. Most dogs on Librela receive ongoing monthly injections as long as the treatment remains beneficial and well-tolerated.
Sources & References
- FDA. “FDA Approves First Monoclonal Antibody for Dogs.” CVM Update, May 2023. https://www.fda.gov/animal-veterinary/cvm-updates
- FDA. “Animal Drug Safety-Related Labeling Changes --- Librela (NADA 141-562).” February 18, 2025. https://www.fda.gov/animal-veterinary/safety-health/animal-drug-safety-related-labeling-changes
- FDA. “Dear Veterinarian Letter --- Librela.” https://www.fda.gov/animal-veterinary/product-safety-information
- Zoetis. “Librela Product Information.” https://www.zoetis.com/products/dogs/librela
- Merck Veterinary Manual. “Osteoarthritis in Dogs.” https://www.merckvetmanual.com/musculoskeletal-system/osteoarthritis
- Vetmeds.org. “Librela Label Update Alert.” February 2025. https://www.vetmeds.org
Verification Notes
- Librela as the first FDA-approved monoclonal antibody for canine OA pain is verified per fact-check report (C5, rated True, High confidence) and FDA CVM update.
- The February 18, 2025 label update adding neurologic adverse events (ataxia, seizures, paresis, proprioception deficits, paralysis) and death reports is verified per fact-check report (C6, rated True, High confidence) and FDA Animal Drug Safety-Related Labeling Changes records.
- The framing of adverse events as “reported outcomes” rather than confirmed causal effects follows the fact-check recommendation for responsible risk communication --- avoiding both minimisation and overstatement.
- Over 18 million global doses and over 1 million US dogs treated are per Zoetis corporate communications.
- Solensia efficacy data (77% owner-reported improvement) is per the Zoetis clinical trial submitted to the FDA.
- Lenivia (izenivetmab) EU authorisation in December 2025 and 3-month duration are per Zoetis pipeline communications and EMA records.